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Abstract
Some drugs currently used are inhibitors of enzymes involved in mediating many disease 
processes. Concerns over the toxicity and side effects of synthetic enzyme inhibitors have 
led to a search for new safe and effective inhibitors particularly from natural sources. 
Owing to their wide range of biological effects, plant phenolic compounds are one of the 
most studied families of natural products. This chapter aims to provide an overview of 
the potential of phenolic compounds as enzyme inhibitors. Extensive research has been 
conducted to study the enzyme inhibitory capacity of many phenolic compounds against 
several enzymes linked with important human conditions. Investigations conducted are 
mainly focused on the inhibition of angiotensin I-converting enzyme, α-amylase and 
α-glucosidase, lipase, cholinesterases, proinflammatory enzymes (cyclooxygenases and 
5-lipoxygenase) and tyrosinase, which are related with hypertension, type II diabetes, 
obesity, Alzheimer’s diseases, inflammation and skin hyperpigmentation, respectively. 
Overall, among phenolics, flavonoids are probably those with great capacity to inhibit 
the activity of the enzymes revised. Several studies demonstrated the potent antioxidant 
and anti-inflammatory properties of flavonoids, which highlight the therapeutic poten-
tial of these compounds. Although our literature survey showed that a huge number 
of phenolic compounds have been studied and there are some promising compounds 
depending on the enzyme, more in vivo tests and subsequent steps to be a drug candidate 
are required before therapeutic application.
Keywords: Alzheimer’s disease, diabetes, flavonoids, hyperpigmentation, hypertension, 
inflammation, obesity
1. Introduction
Due to their essential catalytic role in several physiological processes, enzymes are considered 
to be one of the most attractive targets for drug intervention in human diseases [1]. Indeed, 
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the therapy of some important human aliments, namely hypertension, metabolic disor-
ders, inflammatory diseases and neurodegenerative diseases, includes the use of enzyme 
inhibitors. Nevertheless, some of the inhibitors currently in use (Table 1) are reported to 
have side effects, including hepatotoxicity, gastrointestinal disturbances and diarrhea [2–4]. 
Consequently, there is a great interest in finding new effective natural inhibitors without 
undesirable effects.
The discovery of enzyme inhibitors to be used in human therapeutics is an active and actual 
area of research. Several studies provided evidence about the beneficial effects of phenolic 
compounds in human health due to their wide range of biological properties, namely anti-
oxidant, anticancer, and antimicrobial [5]. The biological actions of phenolic compounds 
involve different mechanisms including the interaction with enzymes [6]. In the last years, 
a great number of reports were published describing the inhibitory potential of phenolic 
compounds against human enzymes. The present chapter aims to systematize the informa-
tion about the enzyme inhibitory properties of phenolic compounds against key enzymes 
associated to several human diseases, namely angiotensin I-converting enzyme, α-amylase, 
α-glucosidase, lipase, cholinesterases, cyclooxygenases (COXs), 5-lipoxygenase (5-LOX) and 
tyrosinase.
2. Human diseases and phenolic compounds
Chronic diseases or non-communicable diseases are adverse health conditions of long dura-
tion and, generally, also of slow progression, causing 63% of all deaths worldwide (36 million 
out 57 million global deaths) [7, 8]. These diseases can be classified into five main groups: 
cardiovascular diseases; cancer; chronic respiratory diseases, such as chronic obstructed pul-
monary disease and asthma; diabetes; and neurodegenerative diseases, such as Parkinson’s 
and Alzheimer’s diseases. Hypertension is one of the major risk factors for cardiovascular 
diseases and is estimated to affect one-third of the Western population [9]. Obesity is also 
considered a global epidemic problem and is associated with multiple chronic diseases [10]. 
Overproduction of oxidants and chronic inflammation is responsible for the pathogenesis 
of many chronic diseases, and experimental and epidemiological studies demonstrated that 
plant antioxidants play an important role in the prevention and treatment of these diseases. 
Diseases Enzyme Main standard inibitor(s)
Hypertension Angiotensin-converting enzyme Aptopril, benazepril, enlapril
Diabetes α-Amylase and α-glucosidase Acarbose
Obesity Pancreatic lipase Orlistat
Alzheimer’s diseases Cholinesterases Tacrine, donepezil, rivastigmine, galantamine
Inflammation Cyclooxygenases and 5-lipoxygenase Indomethacin
Skin hyperpigmentation Tyrosinase Kojic acid
Table 1. Some standard enzyme inhibitors commonly used.
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 Plant-derived antioxidants, particularly phenolic compounds, can reduce the oxidative stress 
in the body maintaining, a balance between oxidants and antioxidants due to their reduc-
ing, free radical scavenging or metal chelating properties [8]. Phenolic compounds can easily 
donate hydrogen from hydroxyl groups positioned along the aromatic ring to terminate free 
radical oxidation of lipids or other biomolecules, and the aromatic phenolic ring can stabilize 
and delocalize the unpaired electron within its aromatic ring [11].
More than 8000 different structures of phenolics have been identified up to now [12]. Phenolics 
may be classified into different groups depending upon the number of phenol rings and the 
structural elements that bind these rings to one another [13]. The main groups of phenolic 
compounds are flavonoids, phenolic acids, tannins, stilbenes and lignans [13]. Flavonoids 
are probably the most important group of phenolic compounds. These are molecules of low 
molecular weight that have a common C6–C3–C6 structure consisting of two aromatic rings 
(A and B) linked through a three carbon chain, usually organized as an oxygenated hetero-
cycle (ring C) (Figure 1) [6]. Flavonoids can be characterized as flavanones, flavones, flavo-
nols, isoflavones, flavanols (essentially, flavan-3-ols) and anthocyanidins. This classification 
depends on the degree of unsaturation and oxidation of the oxygenated heterocycle [6]. Many 
authors demonstrated that the position and number of substituents in the flavonoid basic 
structure significantly affect the biological function [6, 14].
The biological action of phenolic compounds involves different mechanisms including 
nonspecific and specific mechanisms [6]. Nonspecific mechanisms are for instance the 
free radical scavenging and metal sequestration capacity of phenolic compounds and 
their interactions with membranes. On the other hand, specific mechanisms include 
Figure 1. Chemical structure of selected flavonoids. Adapted from Fraga et al. [6].
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the  interaction of  phenolics with enzymes, with transcription factors or with receptors. 
The complexity of some diseases leads to the recent search for alternative therapeutic 
strategies based on combined therapy protocols and multifunctional compounds. Thus, 
phenolic compounds, showing a wide range of biological effects through different mecha-
nisms, have a great potential to be used in the prevention and treatment of several human 
 diseases (Figure 2).
3. Enzyme inhibitors
Enzyme inhibitors can have many applications in pharmaceutical, environment and biochem-
ical industries, having a great impact on healthcare and medical sector. The control of some 
important human diseases includes the use of enzyme inhibitors which represent a great part 
of the drugs in clinical use. Specific enzyme inhibition will remain a major focus of phar-
maceutical research for the foreseeable future [1]. Enzymes are protein molecules acting as 
catalyst in biological systems. Enzymes specificity assures high coordination and harmonious 
interplay among different metabolic activities essential to sustain life. The enzyme activity 
depends on numerous factors, for example, the most important the enzyme concentration, 
Figure 2. Snapshot of some of the health benefits of phenolic compounds.
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the amount of specific enzyme substrate, the electrochemical reaction of medium for enzyme 
activity (pH) and the presence of activators or inhibitors.
Enzyme inhibitors prevent enzymes from their catalytic function by interfering with any 
step in the catalytic cycle. They are low molecular weight compounds that in small quantity 
can reduce or completely inhibit the enzyme activity [15]. Some human enzyme inhibitors, 
such as antithrombin and antitrypsin, control the enzyme activity in the body, and under 
 physiological conditions, they guarantee their action. Among natural enzyme inhibitors, 
there are intermediary products produced during some metabolic pathways. The inhibition 
of products is a restricted way of control or modulation of substrate flux through the pathway. 
If enzymes are sensitive to product inhibition, the output of end product of the pathway will 
be suppressed [16].
An inhibitor can modify one amino acid or several side chain(s) required in enzyme cata-
lytic activity. To protect enzyme catalytic site from any change, ligand binds with criti-
cal side chain in enzyme. Enzyme inhibitors are conceptually classified as specific and 
nonspecific. Inhibitors can reduce or completely inhibit the enzyme catalytic activity 
reversibly or irreversibly. Irreversible inhibitors usually change the enzyme chemically. 
Reversible inhibitors bind non-covalently to produce different types of inhibition, depend-
ing on whether these inhibitors bind the enzyme, the enzyme-substrate complex, or both. 
Most drugs that function through enzyme inhibition interact with their target enzyme 
through simple, reversible binding mechanisms [1]. Reversible inhibitors can be classified 
into competitive, noncompetitive or uncompetitive (Figure 3). In competitive inhibition, 
the substrate and inhibitor cannot bind to the enzyme at the same time; therefore, the 
competitive inhibitor competes with the substrate for the active site. A noncompetitive 
inhibitor binds equally well to both free enzyme and the enzyme-substrate complex. An 
uncompetitive inhibitor binds exclusively to the enzyme-substrate complex yielding an 
inactive enzyme-substrate-inhibitor complex.
4. Phenolic compounds as inhibitors of enzymes linked with human 
diseases
The use of plant-based enzyme inhibitors is encouraged nowadays because there is con-
cern about the critical side effects of synthetic pharmaceutical agents. In the follow-
ing sections, the enzyme inhibitory properties of phenolic compounds are reviewed. 
Investigations have been mainly focused in angiotensin I-converting enzyme, α-amylase 
and α-glucosidase, lipase, cholinesterases, proinflammatory enzymes (COXs and 5-LOX) 
and tyrosinase, which are linked with hypertension, type II diabetes, obesity, Alzheimer’s 
diseases, inflammation and skin hyperpigmentation, respectively (Table 2). These were 
selected to be included in this chapter although there are evidences of the inhibitory prop-
erties of phenolic compounds against other enzymes like monoamine oxidase and cate-
chol-O-methyl transferase.
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Figure 3. Scheme representative of the three major forms of reversible inhibitor interactions with enzymes: (1) 
competitive inhibition; (2) noncompetitive inhibition; (3) uncompetitive inhibition. S: Substrate; E: free enzyme (E); ES: 
enzyme-subtract complex; I: inhibitor; ESI: enzyme-subtract-inhibitor complex. Adapted from Copeland [17].
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4.1. Hypertension: inhibition of angiotensin-converting enzyme (ACE)
Hypertension is a common and often progressive disorder that poses a major risk for car-
diovascular diseases and related complications [18]. Hypertension is an important and 
increasing public health problem worldwide, and some data indicate that about one-quarter 
of the adult population suffers from this condition [19]. Inhibition of angiotensin-converting 
enzyme (ACE) is considered to be a target for discovery of lead antihypertensive agents and 
an important therapeutic approach in the treatment of high blood pressure [20]. ACE catalyzes 
the conversion of the precursor angiotensin I into angiotensin II, a peptide responsible for 
triggering vasoconstrictive effects, and it degrades bradykinin, a potent vasodilator [21, 22]. 
Some of the widely used ACE inhibitors such as aptopril, benazepril, enlapril and other [23] 
have revealed certain limitations like susceptibility to proteolytic degradation leading to side 
effects. Therefore, research has been conducted to find new ACE inhibitors from natural sources 
particularly from plant origin. Many investigations indicate that polyphenol-rich food is effec-
tive in the protection and treatment of hypertension namely via ACE inhibition [24]. In a recent 
review, Patten et al. [25] described 74 families of plants that exhibited significant ACE inhibi-
tory activity. Also, Field and Newton [26] have shown that cocoa polyphenols are bioavailable 
molecules that induce an antihypertensive response including through ACE inhibition.
Guerrero et al. [14] evaluated the ability of 17 flavonoids belonging to five structural sub-
types to inhibit ACE and showed that the highest activity was obtained for luteolin. Results 
from these authors allow concluding that the combination of substructures on the flavonoid 
skeleton that increase ACE activity is made up of the catechol group in the B-ring, the double 
Diseases Enzyme Compound(s) Important references
Hypertension Angiotensin-converting enzyme Flavonoids [14]
Tannic acid [19]
Anthocyanins [27]
Proanthocyanidins [28]
Diabetes α-Amylase and α-glucosidase Flavonoids [37, 39, 40]
Obesity Pancreatic lipase Flavonoids, phenolic acids [47]
Alzheimer’s diseases Cholinesterases Flavonoids [53, 54]
Coumarins [59]
Inflammation Cyclooxygenases and 
5-lipoxygenase
Flavonoids [62, 64–67]
Stilbenes [61, 62]
Skin hyperpigmentation Tyrosinas Flavonoids [71, 73]
Stilbenes [72, 74, 75]
Chalcones [72]
Table 2. Main phenolic compounds described as inhibitors of enzymes linked with human ailments.
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bond between C2 and C3 at the C-ring and the cetone group in C4 at the C-ring. Al Shukor 
et al. [19] investigated the ACE-inhibitory capacity of 22 phenolic compounds belonging 
to different classes and subclasses. Among analyzed compounds, tannic acid exhibited the 
highest ACE-inhibitory activity. Results indicated that the number of hydroxyl groups on 
the benzene ring plays an important role for activity of phenolic compounds and that sub-
stitution of hydroxyl groups by methoxy groups decreased activity. Furthermore, phenolic 
acids and flavonoids inhibit ACE via interaction with the zinc ion, and this interaction is 
stabilized by other interactions with amino acids in the active site. Resveratrol and pyrogal-
lol may inhibit ACE via interactions with amino acids at the active site blocking the catalytic 
activity of ACE [19].
Several studies suggest anthocyanins as important ACE inhibitors. Ojeda et al. [27] demon-
strated the ACE-inhibitory capacity of the anthocyanins delphinidin-3-O-sambubioside and 
cyanidin-3-O-sambubioside isolated from Hibiscus sabdariffa, a plant used in folk medicine, as 
antihypertensive. Moreover, kinetic determinations suggested that those compounds inhibit 
the enzyme activity by competing with the substrate for the active site. Studies from Eriz et al. 
[28] with Vitis vinifera extracts demonstrated that the inhibitory activity of proanthocyanidins 
(condensed tannins) against ACE is associated to a higher availability of OH groups, larger 
mean degree of polymerization and presence of epicatechin gallate.
4.2. Type II diabetes mellitus (DM): inhibition of carbohydrates-hydrolyzing enzymes
Disorders of carbohydrate uptake may cause severe health problems such as diabetes, obe-
sity and oral diseases [29]. Diabetes mellitus (DM) is one of the most serious and chronic 
diseases and can be attributed to hyperglycaemia, a condition characterized by an excessive 
concentration of glucose circulating in the blood. Two types of DM are known, type I that is 
characterized by insufficient insulin production and type II that results from ineffectiveness 
of insulin [30]. Type II DM accounts for approximately 90% of diabetes cases worldwide and 
is attributed to greater prevalence of sedentary lifestyle, unhealthy diet and rise of obesity 
within modern society as well as an increasing number of elderly populations [31, 32]. Type II 
DM has become a serious medical concern worldwide and is frequently correlated with many 
complications such as cardiovascular diseases, hypertension, kidney failure, blindness, and 
neurological complications [33].
One therapeutic approach for treating DM type II is to decrease the postprandial glucose 
levels, which could be done by retarding the absorption of glucose through the inhibition 
of the carbohydrates-hydrolyzing enzymes, α-amylase and α-glucosidase, in the digestive 
tract. These enzymes are responsible for the breakdown of oligosaccharides and disaccha-
rides into monosaccharides suitable for absorption. Inhibitors of these enzymes delay the rate 
of glucose absorption by preventing carbohydrate digestion and consequently blunting the 
postprandial plasma glucose rise [34]. The use of synthetic agents as acarbose is an important 
clinical strategy for controlling postprandial glycemia [35]. Acarbose reduces blood glucose 
levels and is approved by Food and Drug Administration (FDA); however, it causes critical 
side effects, such as liver disorders [4], and its use is now restricted [36]. To avoid or decrease 
the adverse effects of currently used synthetic inhibitors, it is necessary to employ naturally 
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occurring alternatives. In the last years, several reviews have been published focusing on the 
antidiabetic potential of natural products including on the inhibitory properties of pheno-
lic compounds against carbohydrates-hydrolyzing enzymes [29, 30, 37, 38]. Phenolic com-
pounds have been receiving much attention for controlling the digestibility of starch [30], 
and flavonoids are widely studied as α-amylase inhibitors [37]. Tadera et al. [39] tested sev-
eral flavonoid compounds for their inhibitory activity against α-amylase and showed that, 
in  general, the potency of inhibition is correlated with the number of hydroxyl groups on 
the B ring of the flavonoid scaffold. The structural requirements for the inhibition of human 
salivary α-amylase by 19 flavonoids were studied by Lo Piparo et al. [40]. Author’s findings 
demonstrated that the flavonols and flavones enzyme inhibitory capacity depend on hydro-
gen bonds between the hydroxyl groups of the polyphenol ligands and the catalytic residues 
of the binding site and formation of a conjugated α-system that stabilizes the interaction with 
the active site. Recently, Xiao et al. [37] revised the structure-activity relationship of polyphe-
nols inhibiting α-amylase and concluded that the hydroxylation galloylation of flavonoids, 
including catechins, improved the inhibitory effects against α-amylase. Moreover, these 
authors also observed that the glycosylation of the hydroxyl group, methylation, methoxyl-
ation and the hydrogenation of the C2-C3 double bond on flavonoids decreased the inhibition 
of the enzyme.
There are also some reports describing the inhibitory properties of other classes of phenolic 
compounds, like hydroxycinnamic acids and tannins, against α-amylase and α-glucosidase; 
however, overall they are less effective than flavonoids [29, 37].
Phenolic compounds, in particular flavonoids, may provide a protective effect against hyper-
glycemia-induced chronic diseases through a dual protection: inhibition of starch digestion 
and antioxidant effect. The co-application of phenolics with synthetic enzyme inhibitors 
for controlling prosprandial glycemia may reduce the effective dose of synthetic inhibitors 
required [30].
4.3. Obesity: inhibition of pancreatic lipase
Obesity is considered a global epidemic problem by the World Health Organization (WHO) 
and is recognized as the main life style disorder in developing countries, being termed as the 
“New World Syndrome.” It is associated with multiple chronic diseases and disabilities such 
as dyslipidemia, fatty liver disease, osteoarthritis, hypertension, obstructive sleep apnea, gall-
stones, type II diabetes, reproductive and gastrointestinal cancers, coronary artery disease, 
heart failure and stroke [10, 41, 42].
The methods used to reduce body weight include diet, exercise, drug therapy, bariatric sur-
gery or combinations of several of these methods. Currently, orlistat (Xenical) is the only drug 
approved by FDA for long-term treatment of obesity [43, 44]. Orlistat reduces intestinal triglyc-
eride absorption through inhibition of pancreatic lipase. Its long-term administration is associ-
ated with a small but statistically significant weight loss of about 3% more than diet alone in 
overweight and obese people [45]. Moreover, it can also decrease blood pressure, prohibit the 
onset of DM type II and improve oral glucose tolerance [44]. However, some adverse gastro-
intestinal effects of orlistat have been reported as steathorrhea, bloating, oily spotting, fecal 
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urgency and fecal incontinence, as well as hepatic adverse effects [2]. Thus, there has been an 
increase interest in the search for new natural substances that show potent inhibitory activity 
against pancreatic lipase with fewer side effects. As a result, many plant extracts and com-
pounds have been screened for their capacity to inhibit pancreatic lipase [44, 46, 47]. Among 
plant compounds, proteins, polysaccharides, saponins, triterpenes and  phenolic compounds 
have shown capacity to inhibit this enzyme [46]. Phenolic compounds have some potential 
efficacy for preventing obesity by inhibiting the activity of enzymes related to fat metabolism 
as pancreatic lipase, lipoprotein lipase and glycerophosphate dehydrogenase [48]. Examples 
of compounds with pancreatic lipase inhibitory capacity are the flavonoid hesperidin from the 
peels of Citrus unshiu, proanthocyanidins from Cassia mimosoides and tea catechins [47, 48]. A 
compilation of recent and significant results of phenolic compounds as pancreatic lipase inhib-
itors can be found in the review recently published by Buchholz and Melzig [47]. Flavonoids 
and phenolic acids are probably the most studied chemical classes of phenolics showing this 
effect [47]. The lipase inhibitory capacity has been documented for more than 70 different fla-
vonoids, and the inhibitory effect depends on the number and position of phenolic hydroxyl 
groups [47]. In the class of phenolic acids, several hydroxybenzoic and hydroxycinnamic have 
shown capacity to inhibit the enzyme. However, hydroxybenzoic acids are less effective than 
hydroxycinnamic acids, and the influence of methoxy groups (less efficient) in the molecule 
and hydroxyl groups (more efficient) can be seen. The carboxy group takes part in the activity 
of these compounds, and the size of the molecule influences the activity [49].
4.4. Alzheimer’s diseases (AD): inhibition of cholinesterases
Alzheimer’s disease (AD), the most common form of dementia, is a progressive age-related 
neurodegenerative disorder. AD rates are predicted to increase enormously, especially in 
developing regions, considering the accelerated aging of human society and the increase in 
life expectancy worldwide. Although the exact pathogenesis of AD still remains to be fully 
elucidated, it is currently considered to be a multifactorial disease. In the early 1970s, post-
mortem studies revealed that choline uptake and acetylcholine release are reduced in the 
brains of AD patients being these reductions associated with substantial presynaptic cholin-
ergic deficits [50]. This led to the establishment of the “cholinergic-deficit hypothesis,” which 
posits that the impairment in the cholinergic function is of critical importance in AD espe-
cially in the brain areas dealing with learning, memory, behavior and emotional responses 
that include the neocortex and the hippocampus. The levels of acetylcholine, a neurotrans-
mitter responsible for the conduction of electrical impulses from one nerve cell to another 
nerve cell, are decreased due to its rapid hydrolysis by acetylcholinesterase (AChE) enzyme 
[3, 50]. Butyrylcholinesterase (BChE) is an enzyme closely related to AChE and serves as a 
co-regulator of cholinergic neurotransmission by hydrolyzing acetylcholine [51]. Some stud-
ies have shown an increased BChE activity in the most affected areas of the brain during the 
development of AD. The inhibition of both AChE and BChE has been documented as criti-
cal targets for the management of AD by an increase in the availability of acetylcholine and 
decrease in the Aβ deposition. However, the brain region contains a small quantity of BChE 
since it is mostly localized in the peripheral tissues. Therefore, the potential advantage of 
selective inhibition of AChE over BChE may include lesser degree of associated side effects 
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due to peripheral inhibition of cholinesterase enzyme [52]. The first drug developed for AD 
based on the cholinergic-deficit hypothesis was tacrine that was approved for the treatment 
of cognitive loss in patients with AD by the FDA in 1993 [3]. Later, other cholinesterase inhibi-
tors, like donepezil (1996), rivastigmine (2000) and galantamine (2001), have been approved 
and used for the management of AD [3, 52]. Due to the limited efficacy and gastrointestinal 
side effects of these drugs, such as nausea and diarrhea, there has been a continuous effort 
to find more effective cholinesterase inhibitors to be used to prolong and improve the life of 
the AD patients [3]. In this sense, plant extracts and compounds have been investigated for 
their role in prevention and treatment of AD including as cholinesterase inhibitors. Several 
investigations described the anticholinesterase effects of many naturally occurring flavonoids 
and newly synthesized flavonoids analogues. Uriarte-Pueyo and Calvo [53] reviewed the ace-
tylcholinesterase inhibitory capacity of 128 flavonoids and conclude that flavones and isofla-
vones are the compounds with higher activity, proving that the carbonyl group at C4 seems 
to be important in this activity. Later on, Anand and Singh [54] discussed the data on the 
effects of flavonoids in various enzyme targets that play an important role in the pathogen-
esis of AD. Some conclusions arising are that isoflavone analogues demonstrate high AChE 
inhibitory activity, as compared to chalcone, flavones and flavanone analogues, suggesting 
that the nature of flavonoid moiety affects AChE inhibition in a great extent. Moreover, differ-
ent moieties capable of interacting with catalytic site of AChE, including benzyl piperidine, 
piperidine, pyrrolidine, have been linked to paraposition of ring B of flavonoid scaffold using 
appropriate spacer to obtain dual-binding AChE inhibitors. Flavonoids may be attractive 
lead compounds for the development of effective and safe anti-AD drugs by modulating the 
enzyme targets in the disease [54].
Other compounds with potent AChE inhibitory activity are coumarins [55], and similar to 
flavonoids, several coumarins analogues have been synthesized, and their enzyme inhibitory 
capacity evaluated. Data on the inhibitory effects of coumarins against cholinesterases have 
been reviewed by several authors [56–58]. Various coumarins obtained from plants particu-
larly from the Angelica genus revealed potent cholineterases inhibitory capacity (Figure 4) 
[56–59]. Taking into consideration structure-activity relationships, coumarins that small moi-
eties such as hydroxyl or methoxy attached at C-7 of the coumarin skeleton seem to have a 
lower AChE inhibitory effect, in comparison with coumarins of greater substitutions, such 
as benzyloxy, O–CH
2
–C
6
H
5
, positioned at the same carbon [60]. Additionally, a cyclized iso-
prenoid moiety at C-6 greatly contributes to the increase in AChE inhibition of some couma-
rin derivatives [59]. Moreover, research suggests that furanocoumarins are selective BChE 
inhibitors [56].
Numerous studies showed that phenolic compounds not only exhibit cholinesterase inhibitory 
capacity as potent antioxidant and anti-inflammatory properties, acting to scavenge radicals and 
regulate inflammatory responses; moreover, some of these compounds readily cross the blood-
brain barrier to act on specific targets that have been implicated in the pathogenesis of AD.
4.5. Inflammation: inhibition of proinflammatory enzymes
Several diseases such as diabetes, obesity, cancer, osteoarthritis, atherosclerosis and Crohn’s 
disease are associated with chronic inflammation. The mechanisms of inflammation involve 
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a series of events in which the metabolism of arachidonic acid plays an important role [61] 
COX-1 and COX-2 enzymes catalyze the conversion of arachidonic acid to prostanoids. 
The second pharmacologically relevant metabolic pathway of arachidonic acid is mediated 
by 5-LOX. This enzyme is involved in the biosynthesis of inflammatory mediators named 
leukotrienes. COXs and LPXs are considered proinflammatory enzymes; the former affects 
platelet aggregation, vasoconstriction, vasodilatation and later, the development of ath-
erosclerosis [62]. Both COXs and 5-LOX have received considerable attention because they 
are putative targets for cancer prevention. Nonsteroidal and steroidal anti-inflammatory 
drugs exert their action by inhibiting these proinflammatory enzymes through different 
mechanisms [63]. The nonsteroidal and steroidal anti-inflammatory drugs currently in 
use effectively manage the acute inflammatory reaction; however, in chronic inflamma-
tory states, the long-term treatment with these drugs is followed by severe adverse effects. 
This justifies the search for new and safe anti-inflammatory agents being plant compounds 
good candidates. Recently, there has been interest in the antiinflammatory/immunomodu-
latory potential of flavonoids including their capacity to inhibit the activity of proinflam-
matory enzymes [64–66]. Li et al. [66] demonstrated the anti-inflammatory activity of the 
flavonoid baicalin. This compound inhibits COX-1, COX-2 and 5-LOX activities, decreases 
production of proinflammatory eicosanoids and attenuates edema in an in vivo model of 
inflammation. Butein, another flavonoid, decreased COX-2 expression in cancerous lung 
cells [67]. In addition, flavocoxid, a mixed extract containing the flavonoids baicalin and 
catechin, acts as a dual balanced inhibitor of COX-1 and COX-2 with a significant inhibition 
of 5-LOX [65]. It exerts beneficial effects in several experimental models of inflammation, 
and it has a significant efficacy in management of osteoarthritis and a good gastrointestinal 
tolerability [65].
Figure 4. Chemical structure of some coumarins with cholinesterase inhibitory capacity.
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Stilbenes are another important group of plant compounds with anti-inflammatory proper-
ties. Kutil et al. [61] recently demonstrated that several natural stilbenes are potent inhibi-
tors of proinflammatory enzymes and not only the most extensively studied compound of 
this group, resveratrol (3,5,4′-trihydroxy-trans-stilbene) found in red wine. The same group 
[62] evaluated the inhibitory potential of several wines and 33 phenolic compounds com-
monly occurring in wine against COX-1, COX-2, and 5-LOX. Authors observed that red wines 
were potent inhibitors of all three tested enzymes but the results obtained with isolated com-
pounds could not fully explain the overall activities of the wine. Although trans-resveratrol 
considerably inhibits both COX-1 and COX-2, the activity of this compound alone could 
not be responsible for the overall inhibitory activity. In addition, results also showed that 
piceatannol, luteolin, quercetin, and myricetin were potent inhibitors of 5-LOX, but consider-
ing the ratio between their IC
50
 values and their concentration in wine only piceatannol could 
substantially contribute to the overall activity of red wines. Authors hypothesize that wine 
proanthocyanidins could also contribute to its overall potential since their inhibitory capacity 
against these enzymes was previously described.
4.6. Skin hyperpigmentation: inhibition of tyrosinase
The color of mammalian skin is mainly determined by the degree and distribution of melanin 
pigmentation. Melanin plays an important role in protecting skin from ultraviolet UV dam-
age; however, overproduction of melanin poses not only an esthetic but also a dermatological 
problem. Indeed, some dermatological disorders, such as melasma and age spots, result in the 
accumulation of an excessive level of epidermal pigmentation [68].
Melanin is formed by several oxidative reactions which involve tyrosine and tyrosinase [69]. 
Tyrosinase catalyses three reactions in the biosynthetic pathway of melanin in melanocytes: 
the hydroxylation of tyrosine to L-DOPA and its oxidation to dopaquinone. Following a series 
of oxidoreduction reactions, the intermediate dihydroxyindole DHI and dihydroxyindole 
carboxylic acid are produced and polymerized to form melanins [70]. The inhibition of tyrosi-
nase is one of the major strategies used to treat hyperpigmentation; however, concerns over 
the toxicity and side effects of synthetic inhibitors have led to a search for new safe and effec-
tive tyrosinase inhibitors. Moreover, tyrosinase is also responsible for browning in fruits and 
vegetables, and thus, inhibitors of this enzyme are frequently applied to plant-based foods.
Search of tyrosinase inhibitors is crucial for the development of skin whitening agents but also 
anti-browning and insect control substances. A number of researchers have been dedicated to 
identify inhibitors from natural sources including plants. The largest group of phytochemi-
cals with potent tyrosinase inhibitors belongs to phenolics ranging from the simple ones to 
polyphenolics [71]. Furthermore, flavonoids occupy the largest portion in newly discovered 
natural tyrosinase inhibitors, and their structure is compatible with roles of both substrates 
and inhibitors of tyrosinase [71, 72]. Some flavonoids, such as kaempferol, quercetin, and 
morin, show inhibitory activity against tyrosinase, while others such as catechin and rham-
netin behave as substrates and suppress tyrosinase activity by being a cofactor (catechin) or 
acting as a free radical scavenger (rhamnetin) [72]. For instance, steppogenin, a flavanone 
derivative isolated from Cudrania tricuspidata, showed tyrosinase inhibitory activity much 
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higher than kojic acid, a known inhibitor of this enzyme [73]. The presence of two hydroxyl 
groups located on the aromatic ring at positions 2 and 4 in flavonoids was concluded to be 
necessary for tyrosinase inhibitory activity [71].
Some stilbenes, such as resveratrol, oxyresveratrol, chlorophorin and andalasin, have also 
been reported as having tyrosinase inhibitory properties [72, 74, 75]. The most promising 
inhibitor appears to be oxyresveratrol (32-fold higher inhibitory activity than kojic acid). 
Some of these compounds are sensitive to photo-oxidation, which limits their use in cosmetic 
formulations; however, the acetylated resveratrol derivative triacetyl resveratrol is noted to be 
comparably effective and much more stable than resveratrol [75].
There are also a number of chalcones (the precursors of flavonoids and isoflavonoids), such 
as licochalcone A, kuraridin, kuraridinol, 2,4,20,40-tetrahydroxy-3-(3-methyl-2-butenyl) and 
morachalcone A, with remarkable tyrosinase inhibitory activity [72]. Additionally, due to the 
versatile bioactivity and unique structural motif of chalcones, a number of derivatives have 
been developed as effective tyrosinase inhibitor candidates.
Although a great number of phenolic compounds revealed tyrosinase inhibitory capacity, the 
necessity to clarify the viability of these inhibitors in terms of their skin-whitening efficiency 
has become an urgent task.
5. Concluding remarks
The control of some important human diseases includes the use of enzyme inhibitors; how-
ever, there is some concern about the use of synthetic inhibitors due to their side effects. Thus, 
the use of natural enzyme inhibitors, particularly from plant origin, is encouraged nowadays. 
Indeed, up to date, extensive research has been conducted to study the enzyme inhibitory 
properties of phenolic compounds. Data revised showed that different phenolic compounds 
are efficient inhibitors of the activity of a broad number of enzymes linked with important 
human conditions, such as hypertension, type II diabetes, obesity, Alzheimer’s diseases, 
inflammation, and skin disorders. It is unmistakable that phenolic compounds are multifunc-
tional compounds that provide a wide spectrum of biological actions beneficial for human 
health. These compounds exert their action by different mechanisms and have a huge poten-
tial in the prevention and treatment of several human diseases. Our bibliographic survey also 
indicates that flavonoids are probably the group of phenolic compounds with great capacity 
to inhibit the activity of all the human enzymes analyzed. Several structure-activity relation-
ships studies can be found for some flavonoid compounds. In addition to the enzyme inhibi-
tory capacity, several studies demonstrated the strong antioxidant and anti-inflammatory 
properties of flavonoids which highlights the relevance of these compounds for the preven-
tion and control of diseases involving oxidative stress or inflammation.
For the future, standardized protocols to search potential inhibitors should be designed in 
order to minimize the differences among obtained results. Despite the vast number of pheno-
lic compounds studied in vitro, few compounds have continued to in vivo tests. In addition, 
further studies should be performed to predict drug-likeness and drug ability.
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